Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review

Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib. Grade 4 dermatological toxicities are rare, which present as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lingling, Tang, Jiao, Feng, Jun, Huang, Yongfen, Cheng, Yuexin, Xu, Hao, Miao, Yuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359098/
https://www.ncbi.nlm.nih.gov/pubmed/35957865
http://dx.doi.org/10.3389/fonc.2022.941633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359098/
https://www.ncbi.nlm.nih.gov/pubmed/35957865
http://dx.doi.org/10.3389/fonc.2022.941633

Ejemplares similares